September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
A Comparison of Optical Coherence Tomography Angiography to Fluorescein Angiography for the Imaging of Type 1 Neovascularization
Author Affiliations & Notes
  • Maiko Inoue
    Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
  • Jesse J Jung
    East Bay Retina Consultants, Inc., Oakland, California, United States
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
  • Chandra Bala
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
    The LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, United States
  • Talisa E de Carlo
    New England Eye Center and Tufts Medical Center, Tufts University, Boston, Massachusetts, United States
  • Abtin Shahlaee
    Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Michael A Klufas
    Stein Eye Institute at UCLA, Los Angeles, California, United States
  • Jay S Duker
    New England Eye Center and Tufts Medical Center, Tufts University, Boston, Massachusetts, United States
  • Allen C Ho
    Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, United States
  • Maddalena QUARANTA EL-MAFTOUHI
    Centre Ophtalmologique Rabelais, Lyon, France
  • David Sarraf
    Stein Eye Institute at UCLA, Los Angeles, California, United States
  • K Bailey Freund
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
    The LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York, United States
  • Footnotes
    Commercial Relationships   Maiko Inoue, None; Jesse Jung, None; Chandra Bala, None; Talisa de Carlo, None; Abtin Shahlaee, None; Michael Klufas, None; Jay Duker, Alcon/Novartis (C), Allergan (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (C), CoDa Therapeutics (C), Eleven Biotherapeutics (S), Lumenis (C), Optovue (F), Optovue (C), Santen (C), Thrombogenics (C); Allen Ho, Alcon (C), Allergan (C), Genentech (C), Janssen/J&J (C), Regeneron (C), Second Sight (C), Thrombogenics (C); Maddalena QUARANTA EL-MAFTOUHI, Allergan (C), Bayer (C), EBC (C), Novartis (C); David Sarraf, Genentech (F), Regeneron (F); K Bailey Freund, Genentech (I), Heidelberg Engineering (I), Ohr Pharmaceutical (I), Optos (I), Optovue (I), REGENXBIO (I), ThromboGenics (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maiko Inoue, Jesse J Jung, Chandra Bala, Talisa E de Carlo, Abtin Shahlaee, Michael A Klufas, Jay S Duker, Allen C Ho, Maddalena QUARANTA EL-MAFTOUHI, David Sarraf, K Bailey Freund; A Comparison of Optical Coherence Tomography Angiography to Fluorescein Angiography for the Imaging of Type 1 Neovascularization. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Optical coherence tomography angiography (OCTA) is a new technique that detects vascular structures using motion or flow characteristics, however, the utility of OCTA for managing neovascularization (NV) in a clinic-based setting is currently unclear. We performed a multicenter, retrospective cohort study to determine the sensitivity of OCTA and fluorescein angiography (FA) for detecting Type 1 NV compared with detection using FA and structural OCT as the gold standard.

Methods : A retrospective review of FA, OCT and OCTA (Optovue RTVue XR Avanti SD-OCT device) imaging performed on a consecutive series of 115 eyes of 100 patients with type 1 NV from 5 institutions. Unmasked graders utilized FA and OCT data to determine the diagnosis of Type 1 NV. Masked graders evaluated FA data alone, en face OCTA data alone, and combined en face OCTA with OCT line scans to determine the presence of Type 1 NV. Sensitivity analyses were performed using FA and OCT information as the reference.

Results : Ten eyes were excluded from analysis because they had type 2 or type 3 NV. Type 1 NV was due to age-related macular degeneration (59 eyes), central serous chorioretinopathy (22 eyes), pachychoroid neovasculopathy (2 eyes) and polypoidal choroidal vasculopathy (22 eyes). One-hundred-and-five eyes (53.3% treatment-naïve) were diagnosed with Type 1 NV using the gold standard. Of these, 90 (85.7%) could be detected using en face OCTA and OCT line scans. The sensitivity of FA data alone and en face OCTA data alone for visualizing Type 1 NV was the same (both 66.7%). Significant factors that precluded visualization of NV using en face OCTA included height of pigment epithelial detachment, low signal strength and a treatment-naïve status (P < 0.05, respectively). Type 1 NV visualized with en face OCTA correlated to sites of leakage/staining on FA in 80.3% of cases. In the remaining 15 eyes (19.7%), en face OCTA identified type 1 NV at sites where fluorescein leakage/staining was not observed.

Conclusions : En face OCTA and OCT line scans showed higher sensitivity to detect Type 1 NV than either FA alone and en face OCTA alone. Although it should not be considered a suitable replacement for combined FA with OCT data (gold standard), en face OCTA and adjunctive OCT line scans may be helpful to diagnose type 1 NV noninvasively.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×